Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

NCT01074021 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

480

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancer

Interventions

DRUG: Nimotuzumab
DRUG: placebo plus chemoradiotherapy

Sponsor

Biotech Pharmaceutical Co., Ltd.